Cambria Investment Management L.P. Acquires Shares of 3,148 AbbVie Inc. $ABBV

Cambria Investment Management L.P. acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,148 shares of the company’s stock, valued at approximately $729,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Evolution Wealth Management Inc. purchased a new position in AbbVie in the 2nd quarter valued at approximately $26,000. Caitlin John LLC acquired a new position in shares of AbbVie in the third quarter valued at approximately $33,000. Spurstone Advisory Services LLC acquired a new position in AbbVie in the 2nd quarter valued at $28,000. Redmont Wealth Advisors LLC acquired a new position in AbbVie in the third quarter valued at $41,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the 2nd quarter valued at about $36,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABBV. Evercore cut their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. Morgan Stanley upped their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Finally, Citigroup decreased their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $253.15.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.25% of the stock is owned by corporate insiders.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase‑3 AFFIRM results for risankizumab in moderately‑to‑severely active Crohn’s disease — higher clinical remission and endoscopic response vs. placebo. This materially strengthens AbbVie’s immunology growth runway (Skyrizi label expansion) and has driven valuation attention and buying interest. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: Regulatory/portfolio wins: AbbVie reported FDA approval for an oral VENCLEXTA + acalabrutinib combo in previously untreated CLL and is advancing venetoclax into a Phase‑2 program in rare blood cancers (Japan). These expand hematology revenue potential and diversify growth beyond immunology. AbbVie’s New Data And Approval Test Growth And Valuation Story
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) published Medical Weight Loss data showing shifting patient demand that supports aesthetic product adoption and long‑term revenue diversification. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA
• Neutral Sentiment: Market commentary/technicals: Analyst and market pieces show ABBV stabilizing near resistance levels — useful for short‑term traders but not a fundamental catalyst. AbbVie: Stabilizes Near $233 While Testing Resistance
• Neutral Sentiment: Investor events: Management will present at Leerink (Mar 10) and recently at TD Cowen — watch these for updated guidance, commercialization cadence for Skyrizi/Rinvoq, and use of capital commentary. AbbVie to Present at the Leerink Partners Global Healthcare Conference
• Negative Sentiment: Large senior‑notes issuance: AbbVie completed an underwritten public notes offering totaling roughly $7.5–$8.0 billion. Increased debt issuance can pressure credit metrics and investor sentiment despite likely strategic uses (refinancing, liquidity). Monitor yields and management commentary on use of proceeds. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Negative Sentiment: Policy/legal headwind: AbbVie lost its bid to block Tennessee’s 340B law, which could pressure pricing/reimbursement dynamics in certain channels and adds regulatory risk to the top‑line outlook. AbbVie loses bid to block Tennessee 340B law

AbbVie Stock Up 0.9%

Shares of NYSE ABBV opened at $235.90 on Thursday. The stock has a market cap of $417.11 billion, a P/E ratio of 99.96, a P/E/G ratio of 0.81 and a beta of 0.34. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm’s 50-day simple moving average is $224.68 and its 200 day simple moving average is $223.75.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period last year, the firm earned $2.16 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.9%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.